StockNews.AI
REPL
StockNews.AI
3 hrs

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating claims against Replimune. 2. A class action complaint was filed alleging misleading statements. 3. Defendants allegedly overstated IGNYTE trial prospects leading to FDA issues. 4. Investors during November 2024 to July 2025 may have suffered losses. 5. Law firm encourages affected investors to discuss their legal options.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The class action claims suggest significant governance issues and potential financial liability. Similar cases have led to sharp price drops for companies with loss of investor confidence.

How important is it?

The class action lawsuit could undermine investor confidence, impacting REPL’s reputation and share price.

Why Short Term?

Legal proceedings could materially impact REPL's stock price soon. Historically, such announcements lead to immediate market reactions.

Related Companies

BMYMRKNVS
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Replimune Group, Inc. (NASDAQ:REPL) on behalf of long-term stockholders following a class action complaint that was filed against Replimune on July 24, 2025 with a Class Period from November 22, 2024 and July 21, 2025. Our investigation concerns whether the board of directors of Replimune have breached their fiduciary duties to the company. Details: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. Next Steps: If you are a long-term stockholder of Replimune, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News